To recover your password please fill in your email address
Please fill in below form to create an account with us
ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrate-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the activity and safety of adding Lu-PSMA to enzalutamide in mCRPC not previously treated with chemotherapy; and to identify potential prognostic and predictive biomarkers from imaging, blood, and tissue. |
|
Supported By: |
Prostate Cancer Research Alliance (PCRA; jointly funded by the Australian Government and the Movember Foundation), Endocyte, Astellas Pharma Inc. |
|
Eligibility: |
Men with metastatic prostate cancer, progressing on androgen deprivation therapy, not previously treated with chemotherapy for castration-resistant disease, at high risk of early failure on enzalutamide. |
|
Registration ID: |
NCT04419402 |
|
Participation: |
Australia |
|
Australian Lead Group: |
ANZUP |
|
Status: |
In follow-up |
|
Activation Date: |
7th August 2020 |
|
Chairs: |
A/Prof Louise Emmett |
|
Contact: |